A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in combination with Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma (CL-PTL-130)
Clinical Trial Grant
Administered By
Pediatrics, Hematology-Oncology
Awarded By
Gradalis, Inc.
Start Date
October 4, 2019
End Date
February 16, 2023
Administered By
Pediatrics, Hematology-Oncology
Awarded By
Gradalis, Inc.
Start Date
October 4, 2019
End Date
February 16, 2023